Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,261 to 3,280 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With Viral Sequences | 51 of 1,080 63 of 1,108 | -1.0 points -2.8 to 0.9 | 2,188 | NCT03060629 A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa |
| Intervention vs Control: Proportion of Neonates Exclusively Breastmilk Feeding at Discharge | 959 of 1,083 978 of 1,102 | -0.2 points -2.9 to 2.5 | 2,185 | NCT02811432 Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa |
| Intervention vs Control: Mortality Within 7 Days | 81 of 1,083 83 of 1,102 | -0.1 points -2.3 to 2.2 | 2,185 | NCT02811432 Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa |
| Trastuzumab Emtansine (All Participants) vs Trastuzumab Emtansine (Asian Participants): deaths from any cause | 1,072 of 2,002 77 of 181 | 11.0 points 3.4 to 18.3 | 2,183 | NCT01702571 A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment |
| Trastuzumab Emtansine (All Participants) vs Trastuzumab Emtansine (Asian Participants): serious adverse events | 427 of 2,002 36 of 181 | 1.4 points -5.2 to 6.9 | 2,183 | NCT01702571 A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment |
| Chemotherapy vs Atezolizumab and Chemotherapy: Number of Participants With Adverse Events (AE) | 1,074 of 1,084 1,090 of 1,093 | -0.6 points -1.4 to 0.0 | 2,177 | NCT03498716 A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer |
| Chemotherapy vs Atezolizumab and Chemotherapy: serious adverse events | 173 of 1,084 280 of 1,093 | -9.7 points -13.0 to -6.3 | 2,177 | NCT03498716 A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer |
| Patients at High PAE Practices vs Patients at Low PAE Practices: deaths from any cause | 14 of 1,081 14 of 1,095 | 0.0 points -1.0 to 1.0 | 2,176 | NCT02287883 Impact of Patient Activation and Engagement on Patient-Centered Outcomes of Care in ACOs |
| Intervention Group vs Control Group: Number of Participants Reporting Physical Fights | 227 of 961 283 of 1,215 | 0.3 points -3.2 to 3.9 | 2,176 | NCT02909673 School Based Program to Prevent Teen Dating Violence |
| Boostrix Group vs Adacel Group: Number of Seropositive Subjects With Anti-tetanus (Anti-T) Antibodies | 1,420 of 1,445 723 of 728 | -1.0 points -1.9 to 0.0 | 2,173 | NCT00346073 Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years |
| Foley Bulb Plus Oral Misoprostol vs Oral Misoprostol: Number of Participants With Umbilical Cord Blood pH <7.0 | 3 of 1,085 4 of 1,088 | -0.1 points -0.7 to 0.5 | 2,173 | NCT03407625 Foley Bulb With Oral Misoprostol for Induction of Labor |
| Boostrix Group vs Adacel Group: Number of Seropositive Subjects With Anti-diphteria (Anti-D) Antibodies | 1,269 of 1,444 669 of 727 | -4.1 points -6.6 to -1.4 | 2,171 | NCT00346073 Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years |
| Alirocumab 75 Q2W/Up150 Q2W vs Placebo: deaths from any cause | 17 of 1,087 24 of 1,084 | -0.7 points -1.9 to 0.5 | 2,171 | NCT02957682 Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo |
| Alirocumab 75 Q2W/Up150 Q2W vs Placebo: serious adverse events | 189 of 1,087 216 of 1,084 | -2.5 points -5.8 to 0.7 | 2,171 | NCT02957682 Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo |
| Transdisciplinary Approach vs Multidisciplinary Approach: Dispensing of Psychotropic Medications | 125 of 606 289 of 1,564 | 2.1 points -1.5 to 6.0 | 2,170 | NCT03442322 Optimizing Care for Patients With Dementia |
| Boostrix Group vs Adacel Group: Number of Subjects With Serious Adverse Events (SAEs) | 12 of 1,445 11 of 719 | -0.7 points -1.9 to 0.2 | 2,164 | NCT00346073 Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years |
| Seqirus QIV vs Comparator QIV: Number of Participants With Cellulitis-like Reactions | 0 of 1,618 1 of 545 | -0.2 points -1.0 to 0.1 | 2,163 | NCT02914275 A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age. |
| Boostrix Group vs Adacel Group: Number of Subjects Reporting Emergency Room Visits | 13 of 1,444 6 of 718 | 0.1 points -1.0 to 0.8 | 2,162 | NCT00346073 Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years |
| Boostrix Group vs Adacel Group: Number of Subjects Reporting Hospitalizations | 13 of 1,444 10 of 718 | -0.5 points -1.7 to 0.4 | 2,162 | NCT00346073 Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years |
| Boostrix Group vs Adacel Group: Number of Subjects Reporting the Onset of New Chronic Illnesses | 2 of 1,444 3 of 718 | -0.3 points -1.1 to 0.2 | 2,162 | NCT00346073 Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years |
Code
curl "https://conductscience.org/api/comparisons/v1?page=164"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=164
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03060629-3d2654de",
"title": "Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With Viral Sequences",
"summary": "51 of 1080 against 63 of 1108; risk difference -1.0 points, 95% interval -2.8 to 0.9; NCT03060629, A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa",
"record": "/library/comparisons/NCT03060629-3d2654de",
"nct_id": "NCT03060629",
"kind": "outcome",
"participants": 2188,
"risk_difference": {
"value": -0.009636983553951067,
"lower": -0.02849630005722078,
"upper": 0.009164564578761355
},
"group_1": "51 of 1,080",
"group_2": "63 of 1,108",
"difference": "-1.0 points",
"interval": "-2.8 to 0.9",
"trial_title": "A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa"
},
{
"id": "NCT02811432-69f0ab84",
"title": "Intervention vs Control: Proportion of Neonates Exclusively Breastmilk Feeding at Discharge",
"summary": "959 of 1083 against 978 of 1102; risk difference -0.2 points, 95% interval -2.9 to 2.5; NCT02811432, Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa",
"record": "/library/comparisons/NCT02811432-69f0ab84",
"nct_id": "NCT02811432",
"kind": "outcome",
"participants": 2185,
"risk_difference": {
"value": -0.0019740822109720613,
"lower": -0.028695598463429135,
"upper": 0.024693087986190833
},
"group_1": "959 of 1,083",
"group_2": "978 of 1,102",
"difference": "-0.2 points",
"interval": "-2.9 to 2.5",
"trial_title": "Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=165",
"request_id": "O-Gnt8BnqO9JzPIF"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant